Liver fibrosis may reduce the efficacy of budesonide in the treatment of autoimmune hepatitis and overlap syndrome

Creative Commons License

Efe C., Ozaslan E., KAV T., Purnak T., Shorbagi A., ÖZKAYAR Ö., ...Daha Fazla

AUTOIMMUNITY REVIEWS, cilt.11, sa.5, ss.330-334, 2012 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 11 Sayı: 5
  • Basım Tarihi: 2012
  • Doi Numarası: 10.1016/j.autrev.2011.09.006
  • Dergi Adı: AUTOIMMUNITY REVIEWS
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.330-334
  • Hacettepe Üniversitesi Adresli: Evet

Özet

Background and aim: The aim of the present study was to assess the efficacy and tolerability of budesonide as an alternative first line treatment option for autoimmune hepatitis (AIH) and the overlap syndrome.